ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults

S. J. H. Vijverberg, E. S. Koster, R. Tavendale, M. Leusink, L. Koenderman, J. A. M. Raaijmakers, D. S. Postma, G. H. Koppelman, S. W. Turner, S. Mukhopadhyay, S. M. Tse, K. G. Tantisira, D. B. Hawcutt, B. Francis, M. Pirmohamed, M. Pino-Yanes, C. Eng, E. G. Burchard, C. N. A. Palmer, A. H. Maitland-van der Zee (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.

    METHODS: We performed a meta-analysis of three cohort studies: PACMAN (n=357, age: 4-12 years, the Netherlands), BREATHE (n=820, age: 3-22 years, UK) and PAGES (n=391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signaling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the CAMP (clinical trial, n=172, age:5-12 years, USA), GALA II (n=745, age:8-21, USA) and PASS cohorts (n=391, age:5-18, UK) to test the robustness of the findings. Finally, all results were meta-analyzed.

    RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year,; OR=1.22 (p=0.013) and OR=1.22 (p=0.0017) respectively.

    CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a co-chaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signaling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults. This article is protected by copyright. All rights reserved.

    Original languageEnglish
    Pages (from-to)1051-1059
    Number of pages9
    JournalClinical and Experimental Allergy
    Volume45
    Issue number6
    Early online date23 Jan 2015
    DOIs
    Publication statusPublished - Jun 2015

    Fingerprint

    Young Adult
    Adrenal Cortex Hormones
    Steroids
    Genes
    Asthma
    Glucocorticoids
    Single Nucleotide Polymorphism
    Meta-Analysis
    Glucocorticoid Receptors
    Netherlands
    Cohort Studies
    Clinical Trials

    Cite this

    Vijverberg, S. J. H., Koster, E. S., Tavendale, R., Leusink, M., Koenderman, L., Raaijmakers, J. A. M., ... Maitland-van der Zee, A. H. (2015). ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. Clinical and Experimental Allergy, 45(6), 1051-1059. https://doi.org/10.1111/cea.12492
    Vijverberg, S. J. H. ; Koster, E. S. ; Tavendale, R. ; Leusink, M. ; Koenderman, L. ; Raaijmakers, J. A. M. ; Postma, D. S. ; Koppelman, G. H. ; Turner, S. W. ; Mukhopadhyay, S. ; Tse, S. M. ; Tantisira, K. G. ; Hawcutt, D. B. ; Francis, B. ; Pirmohamed, M. ; Pino-Yanes, M. ; Eng, C. ; Burchard, E. G. ; Palmer, C. N. A. ; Maitland-van der Zee, A. H. / ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. In: Clinical and Experimental Allergy. 2015 ; Vol. 45, No. 6. pp. 1051-1059.
    @article{0f4ea7655a7d4dc78ff378d0ad28f5de,
    title = "ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults",
    abstract = "BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.METHODS: We performed a meta-analysis of three cohort studies: PACMAN (n=357, age: 4-12 years, the Netherlands), BREATHE (n=820, age: 3-22 years, UK) and PAGES (n=391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signaling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the CAMP (clinical trial, n=172, age:5-12 years, USA), GALA II (n=745, age:8-21, USA) and PASS cohorts (n=391, age:5-18, UK) to test the robustness of the findings. Finally, all results were meta-analyzed.RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year,; OR=1.22 (p=0.013) and OR=1.22 (p=0.0017) respectively.CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a co-chaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signaling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults. This article is protected by copyright. All rights reserved.",
    author = "Vijverberg, {S. J. H.} and Koster, {E. S.} and R. Tavendale and M. Leusink and L. Koenderman and Raaijmakers, {J. A. M.} and Postma, {D. S.} and Koppelman, {G. H.} and Turner, {S. W.} and S. Mukhopadhyay and Tse, {S. M.} and Tantisira, {K. G.} and Hawcutt, {D. B.} and B. Francis and M. Pirmohamed and M. Pino-Yanes and C. Eng and Burchard, {E. G.} and Palmer, {C. N. A.} and {Maitland-van der Zee}, {A. H.}",
    note = "This article is protected by copyright. All rights reserved.",
    year = "2015",
    month = "6",
    doi = "10.1111/cea.12492",
    language = "English",
    volume = "45",
    pages = "1051--1059",
    journal = "Clinical and Experimental Allergy",
    issn = "0954-7894",
    publisher = "Wiley",
    number = "6",

    }

    Vijverberg, SJH, Koster, ES, Tavendale, R, Leusink, M, Koenderman, L, Raaijmakers, JAM, Postma, DS, Koppelman, GH, Turner, SW, Mukhopadhyay, S, Tse, SM, Tantisira, KG, Hawcutt, DB, Francis, B, Pirmohamed, M, Pino-Yanes, M, Eng, C, Burchard, EG, Palmer, CNA & Maitland-van der Zee, AH 2015, 'ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults', Clinical and Experimental Allergy, vol. 45, no. 6, pp. 1051-1059. https://doi.org/10.1111/cea.12492

    ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. / Vijverberg, S. J. H.; Koster, E. S.; Tavendale, R.; Leusink, M.; Koenderman, L.; Raaijmakers, J. A. M.; Postma, D. S.; Koppelman, G. H.; Turner, S. W.; Mukhopadhyay, S.; Tse, S. M.; Tantisira, K. G.; Hawcutt, D. B.; Francis, B.; Pirmohamed, M.; Pino-Yanes, M.; Eng, C.; Burchard, E. G.; Palmer, C. N. A.; Maitland-van der Zee, A. H. (Lead / Corresponding author).

    In: Clinical and Experimental Allergy, Vol. 45, No. 6, 06.2015, p. 1051-1059.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults

    AU - Vijverberg, S. J. H.

    AU - Koster, E. S.

    AU - Tavendale, R.

    AU - Leusink, M.

    AU - Koenderman, L.

    AU - Raaijmakers, J. A. M.

    AU - Postma, D. S.

    AU - Koppelman, G. H.

    AU - Turner, S. W.

    AU - Mukhopadhyay, S.

    AU - Tse, S. M.

    AU - Tantisira, K. G.

    AU - Hawcutt, D. B.

    AU - Francis, B.

    AU - Pirmohamed, M.

    AU - Pino-Yanes, M.

    AU - Eng, C.

    AU - Burchard, E. G.

    AU - Palmer, C. N. A.

    AU - Maitland-van der Zee, A. H.

    N1 - This article is protected by copyright. All rights reserved.

    PY - 2015/6

    Y1 - 2015/6

    N2 - BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.METHODS: We performed a meta-analysis of three cohort studies: PACMAN (n=357, age: 4-12 years, the Netherlands), BREATHE (n=820, age: 3-22 years, UK) and PAGES (n=391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signaling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the CAMP (clinical trial, n=172, age:5-12 years, USA), GALA II (n=745, age:8-21, USA) and PASS cohorts (n=391, age:5-18, UK) to test the robustness of the findings. Finally, all results were meta-analyzed.RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year,; OR=1.22 (p=0.013) and OR=1.22 (p=0.0017) respectively.CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a co-chaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signaling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults. This article is protected by copyright. All rights reserved.

    AB - BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.METHODS: We performed a meta-analysis of three cohort studies: PACMAN (n=357, age: 4-12 years, the Netherlands), BREATHE (n=820, age: 3-22 years, UK) and PAGES (n=391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signaling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the CAMP (clinical trial, n=172, age:5-12 years, USA), GALA II (n=745, age:8-21, USA) and PASS cohorts (n=391, age:5-18, UK) to test the robustness of the findings. Finally, all results were meta-analyzed.RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year,; OR=1.22 (p=0.013) and OR=1.22 (p=0.0017) respectively.CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a co-chaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signaling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults. This article is protected by copyright. All rights reserved.

    U2 - 10.1111/cea.12492

    DO - 10.1111/cea.12492

    M3 - Article

    VL - 45

    SP - 1051

    EP - 1059

    JO - Clinical and Experimental Allergy

    JF - Clinical and Experimental Allergy

    SN - 0954-7894

    IS - 6

    ER -